ArticleCancer biology & therapy2022

Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.

Lei Duan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.